Harnessing Bioactive Nanomaterials in Modulating Tumor Glycolysis-associated Metabolism

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2022 Dec 12

PMID 36510194

Authors

Zhengying Gu

Chengzhong Yu

Affiliations

Soon will be listed here.

Abstract

Glycolytic reprogramming is emerging as a hallmark of various cancers and a promising therapeutic target. Nanotechnology is revolutionizing the anti-tumor therapeutic approaches associated with glycolysis. Finely controlled chemical composition and nanostructure provide nanomaterials unique advantages, enabling an excellent platform for integrated drug delivery, biochemical modulation and combination therapy. Recent studies have shown promising potential of nanotherapeutic strategies in modulating tumor glycolytic metabolism alone or in combination with other treatments such as chemotherapy, radiotherapy and immunotherapy. To foster more innovation in this cutting-edge and interdisciplinary field, this review summarizes recent understandings of the origin and development of tumor glycolysis, then provides the latest advances in how nanomaterials modulate tumor glycolysis-related metabolism. The interplay of nanochemistry, metabolism and immunity is highlighted. Ultimately, the challenges and opportunities are presented.

Citing Articles

"Friends or foes": a new perspective of tumour metabolic transcriptional modification.

Shi T, Geng Q, Wang Z, Wen C, Xu J, Jiao Y Cell Death Dis. 2025; 16(1):106.

PMID: 39962057 PMC: 11833121. DOI: 10.1038/s41419-025-07429-y.

MOF-derived intelligent arenobufagin nanocomposites with glucose metabolism inhibition for enhanced bioenergetic therapy and integrated photothermal-chemodynamic-chemotherapy.

Chen L, Yang J, Jia L, Wei X, Wang H, Liu Z J Nanobiotechnology. 2025; 23(1):19.

PMID: 39819479 PMC: 11740360. DOI: 10.1186/s12951-024-03084-1.

SIRT6 deficiency impairs the deacetylation and ubiquitination of UHRF1 to strengthen glycolysis and lactate secretion in bladder cancer.

Wang X, Zhang P, Yan J, Huang J, Shen Y, He H Cell Biosci. 2024; 14(1):153.

PMID: 39709438 PMC: 11663349. DOI: 10.1186/s13578-024-01333-2.

Current hotspots and trends in cancer metabolic reprogramming: a scientometric analysis.

Yang S, Lin M, Hao S, Ye H, Zhang X Front Immunol. 2024; 15:1497461.

PMID: 39588377 PMC: 11586341. DOI: 10.3389/fimmu.2024.1497461.

Cell-surface photochemistry mediated calcium overload for synergistic tumor therapy.

Wang J, Wang W, Shen Q, Lan L, Guan C, Xu X J Nanobiotechnology. 2023; 21(1):335.

PMID: 37726778 PMC: 10510147. DOI: 10.1186/s12951-023-02090-z.

References

Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller K . HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell. 2007; 11(5):407-20. DOI: 10.1016/j.ccr.2007.04.001. View

Tu B, Gao Y, Sun F, Shi M, Huang Y . Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity. Front Pharmacol. 2022; 13:840440. PMC: 8980325. DOI: 10.3389/fphar.2022.840440. View

Shao F, Wu Y, Tian Z, Liu S . Biomimetic nanoreactor for targeted cancer starvation therapy and cascade amplificated chemotherapy. Biomaterials. 2021; 274:120869. DOI: 10.1016/j.biomaterials.2021.120869. View

Ding X, Liu M, Cheng Q, Guo W, Niu M, Huang Q . Multifunctional liquid metal-based nanoparticles with glycolysis and mitochondrial metabolism inhibition for tumor photothermal therapy. Biomaterials. 2022; 281:121369. DOI: 10.1016/j.biomaterials.2022.121369. View

Liu Y, Xiang D, Zhang H, Yao H, Wang Y . Hypoxia-Inducible Factor-1: A Potential Target to Treat Acute Lung Injury. Oxid Med Cell Longev. 2020; 2020:8871476. PMC: 7685819. DOI: 10.1155/2020/8871476. View

Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T . Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013; 13(1):89. PMC: 3849184. DOI: 10.1186/1475-2867-13-89. View

Tang Z, Liu Y, He M, Bu W . Chemodynamic Therapy: Tumour Microenvironment-Mediated Fenton and Fenton-like Reactions. Angew Chem Int Ed Engl. 2018; 58(4):946-956. DOI: 10.1002/anie.201805664. View

Ebert B, Firth J, Ratcliffe P . Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem. 1995; 270(49):29083-9. DOI: 10.1074/jbc.270.49.29083. View

Maret W . The redox biology of redox-inert zinc ions. Free Radic Biol Med. 2019; 134:311-326. DOI: 10.1016/j.freeradbiomed.2019.01.006. View

10.

Mukhopadhyay S, Vander Heiden M, McCormick F . The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Nat Cancer. 2021; 2(3):271-283. PMC: 8045781. DOI: 10.1038/s43018-021-00184-x. View

11.

Wang X, Zhao Y, Shi L, Hu Y, Song G, Cai K . Tumor-Targeted Disruption of Lactate Transport with Reactivity-Reversible Nanocatalysts to Amplify Oxidative Damage. Small. 2021; 17(20):e2100130. DOI: 10.1002/smll.202100130. View

12.

Cruys B, Wong B, Kuchnio A, Verdegem D, Cantelmo A, Conradi L . Glycolytic regulation of cell rearrangement in angiogenesis. Nat Commun. 2016; 7:12240. PMC: 4961802. DOI: 10.1038/ncomms12240. View

13.

Zhao S, Peralta R, Avina-Ochoa N, Delgoffe G, Kaech S . Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. Semin Immunol. 2021; 52:101485. PMC: 8545851. DOI: 10.1016/j.smim.2021.101485. View

14.

Perez de Heredia F, Wood I, Trayhurn P . Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. Pflugers Arch. 2009; 459(3):509-18. DOI: 10.1007/s00424-009-0750-3. View

15.

Li W, Peng C, Lee M, Lim D, Zhu F, Fu Y . TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 2013; 73(23):6938-50. PMC: 3856436. DOI: 10.1158/0008-5472.CAN-13-0913. View

16.

Tak E, Jung D, Kim S, Park G, Jun D, Lee J . Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure. Toxicol Appl Pharmacol. 2016; 314:72-81. DOI: 10.1016/j.taap.2016.11.016. View

17.

Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariame A, Touriol C . Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma. Cancer Res. 2015; 75(13):2619-28. DOI: 10.1158/0008-5472.CAN-14-2524. View

18.

Liu W, Semcheddine F, Guo Z, Jiang H, Wang X . Glucose-Responsive ZIF-8 Nanocomposites for Targeted Cancer Therapy through Combining Starvation with Stimulus-Responsive Nitric Oxide Synergistic Treatment. ACS Appl Bio Mater. 2022; 5(6):2902-2912. DOI: 10.1021/acsabm.2c00262. View

19.

Anton L, DeVine A, Polyak E, Olarerin-George A, Brown A, Falk M . HIF-1α Stabilization Increases miR-210 Eliciting First Trimester Extravillous Trophoblast Mitochondrial Dysfunction. Front Physiol. 2019; 10:699. PMC: 6590495. DOI: 10.3389/fphys.2019.00699. View

20.

Li Y, Jeon J, Park J . Hypoxia-responsive nanoparticles for tumor-targeted drug delivery. Cancer Lett. 2020; 490:31-43. DOI: 10.1016/j.canlet.2020.05.032. View